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Pneumocystis pneumonia (PCP) is a serious risk for HIV-positive patients. Asymptomatic
infection or colonisation with P. jirovecii has been shown to occur frequently. PCR assays
frequently identify such cases, due to their high sensitivity. Quantitative real-time PCR
(qPCR) gene copy number cut-off values have been suggested to differentiate colonisation
and infection; these need to be standardised for routine use. We compared the results of
qPCR with an immunofluorescence assay (IFA) to determine a specific cut-off value.
Methods
From March 2005 through June 2009, induced sputum specimens were collected from adult
patients who were clinically suspected of having PCP, at the Chris Hani Baragwanath Hos-
pital in Gauteng, South Africa. Laboratory diagnosis of PCP was done by a conventional
direct IFA and a qPCR assay. A receiver operating characteristic (ROC) analysis was per-
formed to determine a suitable copy number cut-off value.
Results
P. jirovecii was identified in 51% (156/305) and 67% (204/305) of specimens using IFA and
qPCR, respectively. The cut-off value for the qPCR that best predicted the IFA results was
78 copies/5 μl (area under ROC curve 0.92). The sensitivity and specificity of qPCR using
this cut-off was 94.6% and 89.1%, respectively, compared with the IFA.
Discussion
The results of the ROC curve analysis indicate an excellent predictive value of the qPCR
using the proposed cut-off. However, the IFA test is an imperfect gold standard and so this
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cut-off should not be used in isolation; clinical data should also contribute to the interpreta-
tion of the qPCR result.
Introduction
Pneumocystis pneumonia (PCP) is a frequent opportunistic infection in HIV-positive patients
but also affects other immunocompromised patients [1,2]. Healthy individuals have been
shown to harbor the organism without clinical signs of infection [1,3,4]. These findings suggest
that asymptomatic infection or colonisation occurs frequently, and may play a large role in the
transmission of PCP.
With the rapid advancements in molecular biology, an increasing number of laboratories
are adopting polymerase chain reaction (PCR) as an option for diagnostic testing. However,
resource-limited laboratories continue to use conventional methods, for example immunofluo-
rescence assays (IFA) are still commonly used for the diagnosis of P. jirovecii [5]. PCR, especially
quantitative real-time PCR (qPCR), is a highly sensitive assay compared to most conventional
methods. Nonetheless, this increased sensitivity may result in the identification of cases of colo-
nisation in addition to infection, making results less valuable [6]. DNA copy number cut-off val-
ues to differentiate colonisation and infection for qPCR assays have been suggested but need to
be standardised in local settings for routine use [7–10].
Using data from a PCP study carried out on HIV-infected adults hospitalised with pneumo-
nia, we compared two P. jirovecii diagnostic methods, namely, IFA and qPCR. Furthermore,
we used the qPCR assay to determine a copy number cut-off, with the IFA as the ‘gold stan-
dard’ in our study population.
Materials and methods
Patients’ enrolment and sample collection procedures
The study was done under ethical approval (clearance number M040612) of the Human
Research Ethics Committee (Medical) of the University of the Witwatersrand, Johannesburg,
South Africa. Written informed consent was obtained from subjects admitted with a diagnosis
of pneumonia to the Chris Hani Baragwanath Hospital in Soweto, South Africa. An experi-
enced pulmonologist evaluated patients clinically and radiologically as part of routine care
during 2005–2009. Adult patients (18 years of age) suspected of having PCP were enrolled,
and following nebulised sterile saline inhalation under a trained nurse’s supervision, induced
sputum samples were collected. Specimens were refrigerated at 4˚C and sent on icepacks to
the National Institute for Communicable Diseases for laboratory investigations, which were
done within 24 hours of sample receipt.
Immunofluorescence assay
Induced sputum specimens were pre-digested with 1.4-dithiothreitol (DTT, Roche Diagnos-
tics GmbH, Mannheim, Germany) and then processed for immunofluorescence using the
Light Diagnostics Direct Immunofluorescence Assay (IFA) kit for the detection of P. jirovecii
(Millipore Corporation, Billerica, MA 01821) according to manufacturer’s instructions. Slides
were examined with an ultraviolet light-equipped microscope under 400× magnification for
any fluorescing antibody-antigen complexes. If two or more typical ‘honeycomb’ clumps of P.
jirovecii cysts were seen, the specimen was designated ‘positive’ and categorised subjectively as
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weak positive (+), positive (++), or strong positive (+++). If only one confirmed or suspicious
clump and/or cyst was seen, the result was recorded as ‘possibly positive’. Fluorescing particles
that were markedly smaller than a typical cyst were ignored.
Quantitative real-time PCR
Induced sputa were washed with phosphate-buffered saline (Diagnostic Media Products, Johan-
nesburg, South Africa) to remove DTT from the sample. Samples were digested with bacterial
lysis buffer (Roche Diagnostics) and proteinase K (Roche Diagnostics) for 2 hours at 56˚C. DNA
was extracted using the Roche MagNA Pure Compact (Roche Diagnostics) and the MagNA
Pure Compact Nucleic Acid isolation kit (Roche Diagnostics), as per the manufacturer’s instruc-
tions for the bacterial lysis protocol. Extracted DNA (100 μl/sample) was frozen at -70˚C. Fungal
load was determined with a qPCR assay targeting a gene region coding for the P. jirovecii mito-
chondrial large subunit (MtLSU) rRNA, as previously described [11], using a Life Technologies
7500 Real-time PCR Instrument (Life Technologies, Foster City, California). Oligonucleotide
primers and probe were commercially synthesised; forward primer LSU1 (5´-AAATAA ATA
ATC AGA CTA TGT GCG ATA AGG-3´), reverse primer LSU2 (5´-GGGAGC TTT AAT TAC
TGT TCT GGG-3´) and probe LSUP1 (FAM 5´-AGATAG TCC AAA GGG AAA C-3´TAMRA).
Result analysis was done with the Life Technologies 7500 System Software. Real-time PCR results
were extrapolated from a standard curve and were expressed as target sequence copy number
per 5 μl of extracted DNA. This is further referred to as the ‘fungal load’ and correlates with the
qPCR cycle threshold (Ct) values. A fungal load greater than zero was taken as a positive DNA
result. Samples that were IFA-positive and qPCR-negative were tested for PCR inhibition using
an RNaseP PCR, as previously described [12]. Samples were tested once each by IFA and qPCR;
positive and negative controls were used for both assays.
Statistical analysis
To determine the statistical measures of performance of the qPCR assay, the IFA-possibly posi-
tive results were combined with the IFA-positive results. We used a receiver operating charac-
teristic (ROC) analysis to determine the optimal fungal load/Ct value cut-off of the qPCR in
relation to the IFA results (considered as the gold standard in this study). We then estimated
the sensitivity, specificity, positive and negative predictive value of the assay using the identi-
fied cut-off value. The performance of the identified cut-off value was assessed by calculating
the area under the ROC curve.
Results
Patients
During the study period, 266 adult patients with clinically-suspected PCP were recruited. The
median patient age was 34 years, and the ratio of males to females was 1:1.3. All patients were
either laboratory confirmed as, or highly suspected on clinical grounds to be, HIV-positive. A
total of 305 respiratory specimens was collected for testing; some patients had more than one
sample collected during their hospital stay.
Immunofluorescence assay
Of the 305 specimens tested for P. jirovecii by the IFA detection method, 51% (156/305) were
IFA positive, 4% (11/305) were IFA possibly positive and 45% (138/305) were IFA negative.
Fig 1 shows two fluorescing clusters of P. jirovecii cysts.
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Quantitative real-time PCR
Quantitative real-time PCR was performed on DNA extracts from all 305 specimens. Sixty-
seven percent (204/305) of the specimens were positive for P. jirovecii DNA (i.e. they had a
fungal load greater than 0) (Table 1).
Using the IFA test as the gold standard, the sensitivity and specificity of the qPCR assay
were calculated to be 98.2% and 70.7%, respectively. The positive and negative predictive val-
ues were 80.1% and 96.5%, respectively. There were four false negative qPCR results; these
were tested for PCR inhibition and the IFA slides were re-examined. Two of these specimens
were shown to contain PCR inhibitors, using the RNase P PCR assay. One specimen was
regarded as having an incorrect positive IFA result, as it did not correspond with the typical
morphology of P. jirovecii on slide review.
The median fungal load correlated well with the IFA results (Table 2).
The ROC analysis indicated that, in comparison with the IFA results, the optimal cut-off
value for the qPCR was 78 DNA copies or a Ct value of 38.19, which correctly classified 92.1%
of the IFA results. The area under the ROC curve was 0.92 (95% confidence interval: 0.88–
0.94), which indicates an excellent predictive value of PCR using this cut-off value. The sensi-
tivity and specificity of the qPCR using this cut-off were 94.6% and 89.1%, respectively.
Fig 1. Micrograph showing two fluorescing green clusters of P. jirovecii cysts on a red-stained
background, 400x magnification.
https://doi.org/10.1371/journal.pone.0180589.g001
Table 1. Comparison of the P. jirovecii immunofluorescence assay (IFA) and the quantitative real-time PCR (qPCR) assay results, Soweto, South
Africa, 2005–2009 (N = 305).
IFA Result
Positive Possibly positive Negative Total
qPCR Result Positive 153 10 41 204
Negative 3 1 97 101
Total 156 11 138 305
https://doi.org/10.1371/journal.pone.0180589.t001
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Discussion
In this study, we compared the IFA method to qPCR for the detection of P. jirovecii, in a South
African cohort of immunocompromised patients. This is the first study in South Africa to use
ROC analysis to compare IFA with qPCR. The former method identified 51% of specimens as
positive, and the latter 67%. The IFA staining method allows for the Pneumocystis organisms
to be microscopically identified, whereas the qPCR amplifies target DNA sequences. Therefore
it must be noted that DNA in a specimen could be from dead organisms and therefore may
not be clinically relevant [13].
Using the IFA as the gold standard, the qPCR had 41 false-positive and four false-negative
results. The false-positive results were mostly in specimens with low fungal loads (median
copy number, 45) that were not detected by the IFA. As these specimens had overall lower
median copy numbers of the target gene sequences, compared to the true-positive results, they
may have originated from patients who were colonised rather than infected with P. jirovecii
[13]. If this is true, then these patients probably had other respiratory diseases to account for
their clinical presentations on enrolment. In the USA, a large proportion (69%) of HIV-posi-
tive patients without PCP, were found to be colonised with P. jirovecii using PCR [14].
The four qPCR false-negative results were further investigated. Two specimens contained
PCR inhibitors, one was deemed a false-positive IFA result (reader error) on slide review and
the last one was assumed to be due to unidentified technical error. The IFA method has been
shown to have the highest sensitivity but the lowest specificity when compared to three other
staining methods [5]. Non-specific staining is a limitation of IFA kits for P. jirovecii [15], espe-
cially if coupled with inexperienced microscopists. The strict use of defined morphological cri-
teria, as we did, should improve the specificity of IFA. Khan et al. compared PCR and IFA
assays and concluded that immunofluorescence should not be used solely for the diagnosis of
PCP [13]. They further stated that PCR should be used when the IFA result is negative and the
patient is suspected of having PCP.
A major problem when evaluating tests for PCP diagnosis is the lack of a true gold standard.
This is mainly due to the non-existence of a culture system for P. jirovecii. The IFA test was
chosen as the gold standard in this study because it was the current routine diagnostic test for
PCP used by the laboratory. The use of clinical and radiological criteria may serve as a good
gold standard for P. jirovecii diagnosis, as was used by Fujisawa et al. [16]; however, radiologi-
cal findings were not available for analysis in this study.
Our results showed a good correlation between the qPCR median fungal load and IFA
result i.e. low copy number for IFA-negative specimens and increasingly higher copy numbers
for IFA-possibly positive and IFA-positive specimens. The median copy number was used
Table 2. qPCR fungal load of P. jirovecii DNA for each immunofluorescence assay (IFA) result cate-
gory, Soweto, South Africa, 2005–2009.
IFA result category qPCR assay results expressed as P. jirovecii fungal load (copy number per
5 μl)
Median (range)




IFA-positive 12 270 (7–704 257)
• IFA + • 195 (7–48 923)
• IFA ++ • 1 779 (93–56 260)
• IFA +++ • 23 643 (137–704 257)
https://doi.org/10.1371/journal.pone.0180589.t002
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instead of the mean to reduce the effect of outliers. However, there was a large overlap in the
range of copy numbers in each category. The optimal cut-off value (78 DNA copies/5 μl or Ct
value of 38.19) that was derived from the ROC analysis indicated an excellent predictive value
of this PCR assay when compared against the IFA results. As previously discussed, the IFA test
is not a completely reliable gold standard because it does not always distinguish true infection
from colonisation; therefore this copy number cut-off is subject to this limitation.
There are many publications that have suggested qPCR cut-off values for Pneumocystis
infection and colonisation, including some that incorporate a ‘grey zone’ for indeterminate
results [7,9,10,17–19]. However, these cut-offs cannot be applied to different clinical situations
and different assays [18,20]. When using previously established cut-offs it must be remem-
bered that fungal loads will vary according to study parameters, including study population,
specimen type and quality, and test method used. It has been shown that HIV-infected PCP
patients have higher fungal loads than HIV-negative patients [19–21]. Furthermore paediatric
patients may have different loads compared to adults. Specimen type and quality influences
test results; for PCP, bronchoalveolar lavage and induced sputum samples are accepted to be
the preferred types [1]. A cut-off value established for these sample types cannot be used for
studies done on less-optimal specimen types, such as nasopharyngeal aspirates. Cut-off values
will also vary based on the test methods used; PCR assays have various gene targets, sensitivi-
ties and units of measurement. Therefore from our results, a cut-off value of 78 DNA copies/
5 μl (or a Ct value of 38.19) can be used to differentiate cases of P. jirovecii infection and colo-
nisation when testing induced sputum specimens from HIV-positive patients, using the speci-
fied qPCR assay, in our setting.
It has been suggested that qPCR cut-offs be combined with another test such as IFA or β-
1,3-D-glucan to create a diagnostic algorithm [22,23]. This is especially advisable for routine
diagnostic testing.
In conclusion, while qPCR cut-offs are useful, they cannot be universally applied but should
rather be established using a pilot study with the same study parameters. However, as with
many laboratory tests, irrespective of the method used to diagnose PCP, clinical interpretation,
in light of patient presentation, is the ultimate deciding factor for patient treatment.
Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily rep-
resent the official position of the US Centers for Disease Control and Prevention, USA or the
National Institute for Communicable Diseases, South Africa.
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